Notice of interim results

RNS Number : 4965G

Frontier IP Group plc

17 March 2020

 

RNS

AIM: FIPP

17 MARCH 2020

Frontier IP Group Plc

("Frontier IP" or the "Group")

Notice of interim results

Frontier IP, a specialist in commercialising intellectual property, today announces that it intends to publish its unaudited interim results for the half-year to 31 December 2019 on Wednesday 25 March 2020.

Key developments in the half year included an oversubscribed placing, which raised £3.8 million net of expenses, the incorporation of Elute Intelligence Holdings and Exscientia's collaboration with Rallybio, a US specialist in rare diseases. Results are expected to show significant progress.

Momentum has remained strong into the second half: the Vaccine Group ("TVG") has started work on a COVID-19 vaccine following validation and good progress with its novel vaccine platform technology; TVG and Fieldwork Robotics completed initial equity fundraisings; Cambridge Raman Imaging gained an EU Graphene Flagship grant; and Exscientia entered into a collaboration with Bayer AG. The Company has a robust balance sheet at the current time.

The Group looks forward to providing further details at the time of the interim results on 25 March 2020.

ENQUIRIES

Frontier IP Group Plc
Neil Crabb, Chief Executive Officer Andrew Johnson, Communications & Investor Relations Company website: www.frontierip.co.uk	T: 0207 332 2338 M: 07464 546 025
Allenby Capital Limited (Nominated Adviser)	T: 0203 328 5656
Nick Athanas / Nicholas Chambers  N+1 Singer (Broker) Harry Gooden / George Tzimas	T: 0207 496 3000

ABout frontier IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

END

 

 

NORKKOBDPBKDDND